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Thalidomide plus dexamethasone as a maintenance therapy after
autologous hematopoietic stem cell transplantation improves
progression-free survival in multiple myeloma
Angelo Maiolino,1* Vania T.M. Hungria,2 Marcia Garnica,1 Gislaine Oliveira-Duarte,3 Luciana C.O. Oliveira,4
Daniel R. Mercante,1 Eliana C. Miranda,3 Adriana A. Quero,2 Ana L.M. Peres,2 Jose´ C. Barros,2
Paola Tanaka,2 Roberto P. Magalha˜es,1 Eduardo M. Rego,4 Irene Lorand-Metze,3 Carmen S.P. Lima,3
Ilana Z. Renault,5 Esteban Braggio,5 Carlos Chiattone,2 Marcio Nucci,1 and Carmino A. de Souza3; for the
Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH)
Despite the good response of stem cell transplant (SCT) in the treatment of multiple myeloma (MM), most
patients relapse or do not achieve complete remission, suggesting that additional treatment is needed. We
assessed the impact of thalidomide in maintenance after SCT in untreated patients with MM. A hundred and
eight patients (<70 years old) were randomized to receive maintenance with dexamethasone (arm A; n 5 52)
or dexamethasone with thalidomide (arm B; n 5 56; 200 mg daily) for 12 months or until disease progression.
After a median follow-up of 27 months, an intention to treat analysis showed a 2-year progression-free sur-
vival (PFS) of 30% in arm A (95% CI 22–38) and 64% in arm B (95% CI 57–71; P 5 0.002), with median PFS of
19 months and 36 months, respectively. In patients who did not achieve at least a very good partial response,
the PFS at 2 years was significantly higher when in use of thalidomide (19 vs. 59%; P 5 0.002). Overall sur-
vival at 2 years was not significantly improved (70 vs. 85% in arm A and arm B, respectively; P 5 0.27). The
addition of thalidomide to dexamethasone as maintenance improved the PFS mainly in patients who did not
respond to treatment after SCT. Am. J. Hematol. 87:948–952, 2012. VC 2012 Wiley Periodicals, Inc.
Introduction
High-dose therapy supported by autologous hematopoi-
etic stem cell transplantation (ASCT) has become the
mainstay for the treatment of multiple myeloma (MM) in
patients up to 65 years of age. Compared with conventional
chemotherapy, ASCT has been shown to improve response
rates and prolong progression-free survival (PFS), and
overall survival (OS) [1,2]. Unfortunately, most patients
relapse after ASCT, suggesting that additional treatment is
needed to prolong PFS. Maintenance and/or consolidation
therapies have been shown to improve outcomes in
patients receiving ASCT-based treatment and have a signif-
icant impact on both OS and PFS [3,4].
Thalidomide, an immunomodulatory agent with antiangio-
genic properties, was first introduced as a treatment for
MM in 1999 [5]. The impressive results and acceptable tox-
icity observed in patients with advanced relapses and re-
fractory disease qualified thalidomide as a potential candi-
date for maintenance therapy after ASCT. The use of thali-
domide alone or in association with corticosteroids after
ASCT improved overall response rates, event-free survival,
and OS in two large, randomized clinical trials [3,4]. Based
on these data, the Brazilian MM Study Group designed a
clinical trial to evaluate the impact of thalidomide in mainte-
nance after ASCT.
Methods
This multicenter, prospective, and randomized trial was conducted in
four centers from October 2003 to July 2008. The protocol was
approved by the ethics committee of each center, and all patients
signed an informed consent form before beginning any study proce-
dure. This study was registered at http://clincaltrials.gov as
NCT01296503. Randomization was performed at a central location
using sealed envelopes and computer-generated numbers.
The following were the inclusion criteria used in this study: sympto-
matic MM in accordance with the International Myeloma Working
Group criteria, [6] age 18–70 years, ECOG performance status of 0–2,
and normal hepatic function (defined as serum bilirubin <3 mg/dL and
AST and ALT <4 times normal). Exclusion criteria included evidence of
disease progression after ASCT (before randomization), cardiac dys-
function (systolic ejection fraction <50%), chronic respiratory disease
(carbon monoxide diffusion <50% of normal), or any comorbidity likely
to negatively affect the feasibility of the study.
The treatment consisted of the following four phases: (1) induction
with 3–5 cycles of VAD (vincristine 0.4 mg IV, doxorubicin 9 mg/m2 IV,
and oral dexamethasone 40 mg daily for 4 days) every 21–28 days; (2)
cyclophosphamide (4 g/m2 IV) plus G-CSF (5 lg/kg twice a day) for
stem cell mobilization; (3) melphalan (200 mg/m2 IV) and ASCT; and
(4) Randomization: maintenance therapy with arm A receiving dexa-
methasone alone (40 mg/d PO for 4 days every 28 days) or arm B
receiving dexamethasone (same dose) plus thalidomide (200 mg PO
daily) for 12 months or until disease progression.
Prophylaxis for deep venous thrombosis (DVT) was prescribed at the
discretion of each investigator. The dose of thalidomide could be
reduced if the patient experienced grade 2 or higher adverse events. In
this case, thalidomide was discontinued and was restarted at a lower
dose after the resolution of the adverse event. A bisphosphonate
(clodronate, pamidronate, or zoledronate, depending on the center)
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was given monthly for 24 months starting at the time of induction
therapy.
The response to treatment was evaluated at the end of each phase
of the protocol and every 3–4 months after randomization. The
response was assessed using serum and urine M-protein levels as
measured by electrophoresis and immunofixation. All of these parame-
ters were assessed in a central laboratory. The criteria used to define
response, relapse, and progression were taken from the European
Group for Blood Marrow Transplantation, the International Bone Marrow
Transplant Registry, and the Autologous Blood and Marrow Transplant
Registry [7], with a very good partial response (VGPR) defined as a
greater than 90% reduction in paraprotein levels (Inter-Groupe Franco-
phone du Mye´lome, IFM) [8].
The objective of this study was to evaluate the efficacy of thalidomide
plus dexamethasone as a maintenance therapy after ASCT. The primary
endpoint was PFS, defined as the time from randomization until any docu-
mentation of relapse, progression, or death by any cause. The secondary
endpoints were OS (defined as the interval from randomization to the last
follow-up or death), and the tolerability and safety of thalidomide.
Response was assessed by the investigator and was centrally
reviewed by an independent committee that was blinded to the study
arm. In cases where there was a discrepancy between the investigator
and the blinded committee, the committee’s judgment prevailed.
Adverse events were classified according to the National Cancer
Institute Common Toxicity Criteria, version 2. Safety evaluations were
based on clinical features (medical history and physical examination)
and focused especially on neurological symptoms and the development
of DVT. Adverse event evaluations were performed at the time of
response assessment and whenever a new clinical manifestation sug-
gestive of toxicity appeared. Laboratory safety monitoring consisted of
biochemical, hematological, and urine tests.
For sample size calculations, we considered a PFS of 40% in the
dexamethasone arm [9] and 60% in the dexamethasone 1 thalidomide
arm. Considering the values of a 5 0.05 and b 5 0.20 and an
expected loss of 15% from enrollment to randomization, 228 patients
would be needed (114 patients per arm). Actuarial curves of OS and
PFS were analyzed using the Kaplan-Meier method and were com-
pared by the log-rank test. Categorical data were analyzed using the
Chi-square or Fisher’s exact tests as appropriate and continuous varia-
bles were compared using the Wilcoxon test. We looked at predictors
of outcome (OS and PFS) by performing univariate Cox regression
analysis and selected variables with P values <0.1 to enter into a multi-
variate Cox regression analysis. The following variables were analyzed:
gender, age, Durie-Salmon stage, ISS, baseline hemoglobin, platelet,
and leukocyte count, corrected calcium, b-2 microglobulin, creatinine,
bone marrow plasmacytosis, chromosome 13 deletion (by FISH),
response after VAD, ASCT, and maintenance, and the maintenance
therapeutic arm (dexamethasone or dexamethasone 1 thalidomide).
Two-sided P values <0.05 were considered statistically significant. Sta-
tistical analysis was performed using SPSS 15.0 software (SPSS).
Results
Two hundred and thirteen patients were enrolled and started
the first phase of the protocol (VAD). The median age of the
213 patients was 55 years (range 27–71), and there were 110
males. Most patients had advanced disease at diagnosis (77%
Durie-Salmon stage III, 71% ISS in stages II/III). Chromosome
13 deletion was present in 34% of the 150 patients tested.
Among the 213 patients, 123 (58%) underwent the
scheduled ASCT, and 108 (51% of the enrolled patients
and 88% of the patients who underwent ASCT) were
randomly assigned to maintenance therapy: 52 in arm A
and 56 in arm B (Fig. 1). Ninety patients did not undergo
ASCT for the following reasons: early death (n 5 44,
including 36 deaths during VAD treatment phase and 8 dur-
ing stem cell mobilization phase), lost in follow-up (n 5 22),
progression after VAD (n 5 14), refusal (n 5 4), not eligible
for ASCT due to poor lung or cardiac function (n 5 4), and
Figure 1. Consort chart of the trial based on the consolidated trial reporting standards. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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protocol violation (n 5 2). Among the 123 ASCT recipients,
14 were not randomized for the following reasons: death (n
5 7), disease progression (n 5 5), concomitant myelodys-
plasia (n 5 1), psychosis (n 5 1), and protocol violation (n
5 1).
Table I shows a comparison of the baseline characteris-
tics of the 108 randomized patients. The two groups were
comparable except for a higher median age in arm A (55
vs. 52 years; P 5 0.052) and for a higher proportion of ISS
stage III in arm A (30 vs. 13%; P 5 0.04).
There were no differences in response rates (CR and
VGPR) between the groups 12 months after the initiation
maintenance therapy and at the last follow-up (Table II) in
intention to treat analysis. After a median follow-up of 27
months, the estimated OS at 2 years was 70% in arm A
(95% confidence interval [CI] 60–80) and 85% in arm B
(95% CI 80–90; P 5 0.27; Fig. 2A). The 2-year PFS was
30% in arm A (95% CI 22–38) and 64% in arm B (95% CI
57–71; P 5 0.002; Fig. 2B), with median PFS of 19 months
(range 15–22) and 36 months (range 22–49), respectively.
We looked at OS and PFS in good (CR and VGPR) and
poor (below VGPR) responders after ASCT. The estimated
OS at 2 years did not differ among good and poor responders
(83% in arm A and 89% in arm B, P 5 0.41, for good res-
ponders; 66% in arm A and 82% in arm B, P 5 0.29, for poor
responders). In contrast, patients who did not achieve a CR
or VGPR, the estimated PFS at 2 years was significantly dif-
ferent between the two treatment groups (19% in arm A and
59% in arm B; P 5 0.002; Fig. 3B). This difference was not
observed in patients with CR or VGPR (Fig. 3A).
Multivariate predictors of PFS included the response af-
ter maintenance (hazard ratio [HR] 3.12, 95% CI 1.82–
5.35; P < 0.001) and arm B (HR 2.43, 95% CI 1.43–4.13;
P 5 0.001). For OS, the only significant variable was base-
line hemoglobin (HR 1.26, 95% CI 1.04–1.54).
Since there was an imbalance in the two arms regarding
age and ISS stage, and considering that these variables may
affect the primary endpoint, a Cox regression analysis was
undertaken, including these two variables and the therapeutic
arm only. In this model, the only significant variable was ther-
apeutic arm B (HR 2.43, 95% CI 1.43–4.10, and P 5 0.001).
Thalidomide was given to 49 of the 56 patients in arm B
(87%) during the 12-month period. Forty-six patients (82%)
received 200 mg during the study period. The median dura-
tion of thalidomide treatment in Arm B was 16 months
(ranging from <1 to 51 months). Thalidomide was discontin-
ued in 13 patients: three due to adverse events (neuropathy,
DVT, and skin rash). Grade 3 or 4 adverse events occurred
in four patients in arm A (8%) and in 19 in arm B (33%; P 5
0.001). One patient from arm B experienced two adverse
events. Peripheral neuropathy was observed in 12 patients
receiving thalidomide (21%). Grade 3 or 4 DVT was reported
in only one patient in arm B (Table III).
Discussion
In this study, even with fewer number of patients random-
ized than was target, we confirmed that the use of thalido-
mide in conjunction with corticosteroids following a single
ASCT improves the PFS in patients with MM. The magni-
tude of this effect was greatest among patients who exhib-
ited a poor response after ASCT.
Our PFS findings are similar to those found in previously
published data evaluating the efficacy of a thalidomide-
based regimen after ASCT [3,10–13]. Thalidomide has
been used in MM patients since Barlogie et al. [5] and Sin-
ghal et al. [14] first demonstrated the beneficial activity of
this drug in advanced and refractory disease. In addition, a
powerful synergism between thalidomide and corticoste-
roids has been reported [15]. Maintenance treatment with
thalidomide after ASCT was evaluated in a randomized trial
by the IFM group [3]. The IFM 99-02 trial compared
patients who did not receive maintenance therapy with
those who received thalidomide plus pamidronate therapy
after tandem ASCT and showed that the addition of thalido-
mide improved response rates as well as EFS and OS.
Similar to this study, a greater benefit was observed in
patients who had experienced a response less than VGPR
at the time of randomization, suggesting that the benefit of
thalidomide is to reduce the tumor mass rather than to
maintain a response already obtained with prior therapy.
Some differences in the two studies are worth mentioning.
First, in the IFM trial, maintenance therapy was initiated af-
ter a tandem ASCT, whereas in this study, only one ASCT
TABLE I. Baseline Characteristics of the 108 Patients Randomized to
Receive Dexamethasone (Arm A; n 5 52) or Dexamethasone 1 Thalidomide
(Arm B; n 5 56)
Variable
Arm A;
n 5 52
Arm B;
n 5 56 P value
Age (years); median (range) 55 (27–68) 52 (37–63) 0.052
Gender, male:female 29:23 30:26 0.82
Type of myeloma, n (%) 0.39
IgG 29 (56) 28 (50)
IgA 13 (25) 15 (27)
Light chain 10 (19) 10 (18)
Nonsecretory 0 3 (5)
Serum hemoglobin (g/dL),
median (range)
10.4 (4.0–15.0) 9.9 (4.7–15.2) 0.67
Serum calcium (mg/dL),
median (range)
9.3 (8.2–13.2) 9.4 (5.1–18.1) 0.56
Serum b-2-microglobulin (mg/dL),
median (range)
2.72
(0.20–22.50)
2.86
(0.34–23.80)
0.80
Serum creatinine (mg/dL),
median (range)
1.0 (0.5–8.0) 1.1 (0.6–5.7) 0.70
% Plasma cells in the bone marrow
aspirate, median (range)
20 (13–100) 35 (13–95) 0.27
Chromosome 13 deletion, n (%) 9 (17) 13 (23) 0.45
Stage (Durie-Salmon), n (%) 0.86
IIA 10 (19) 12 (1)
IIB 2 (4) 1 (2)
IIIA 28 (54) 32 (58)
IIIB 12 (23) 11 (19)
International staging system, n (%)a 0.04
I 19/50 (38) 18/54 (33)
II 16/50 (32) 29/54 (54)
III 15/50 (30) 7/54 (13)
Disease status after VAD regimen,
n (%)
0.30
Complete or very good partial
response
8 (15) 5 (9)
Otherb 44 (85) 51 (91)
Disease status at randomization, n (%) 0.49
Complete or very good partial
response
18 (35) 23 (40)
Otherb 34 (65) 33 (60)
Time (days) from ASCT to
randomization, median (range)
116.5 (52–162) 124.5 (30–181) 0.28
a
Data available in 50 patients in arm A and 55 in arm B; VAD 5 vincristine,
doxorubicin, and dexamethasone.
b
Other includes partial remission, minimal response, and disease progression
TABLE II. Response Rate in Patients Receiving Dexamethasone (Arm A;
n 5 52) or Dexamethasone 1 Thalidomide (Arm B; n 5 56)
Response
Arm A;
n 5 52
Arm B;
n 5 56 P value
After 12 months of maintenance 0.84
Complete or very good partial response 25 (48) 28 (50)
Othera 27 (52) 28 (50)
At last follow up 0.90
Complete or very good partial response 20 (38) 23 (40)
Partial response/stable disease 3 (6) 4 (7)
Progressive disease 29 (56) 29 (52)
a
Other includes partial remission, minimal response, and disease progression.
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was performed. In addition, the IMF trial did not use dexa-
methasone. Finally, our study included all patients who met
the inclusion criteria regardless of their prognostic risk
(assessed by b-2 microglobulin serum level and the pres-
ence of chromosome 13 deletion), whereas the IFM trial
included only low-risk patients [3].
A similar strategy using maintenance therapy with thali-
domide after a single ASCT was reported by Spencer et al.
In that trial, thalidomide was also combined with corticoste-
roids (in this case prednisolone), and this treatment
resulted in prolonged PFS and OS. The benefit was
observed in all patients independent of the response before
randomization. Interestingly, the patients who did not
achieve a response of CR or VGPR had longer PFS when
thalidomide was added [4].
Two other randomized studies analyzed the impact of
ASCT in conjunction with thalidomide in newly diagnosed
MM patients, but these studies used different strategies
[10,11]. In these trials, thalidomide was given before and
after ASCT. Thalidomide improved response rates and pro-
longed EFS and PFS, but there was no benefit in terms of
OS. The absence of an effect on OS was attributed to the
fact that relapsed patients in the treatment arms without
thalidomide received salvage therapy with this drug [10,11].
This is also the best explanation for the lack of an improve-
ment in OS observed in our study.
Prolonged EFS or PFS may result in a benefit in OS as
observed in a recent report of the long-term follow-up of
two large clinical trials. In one trial (IFM 99-02), the survival
benefit of thalidomide maintenance therapy that was
reported in the original publication was no longer significant
after 5.7 years of follow-up, but in the other trial (TT2), a
significant benefit was observed after a median of 7.2 years
of follow-up [16].
The impact of thalidomide maintenance therapy on the
OS is definitely controversial. Stewart et al. reported a trial
comparing thalidomide and prednisone versus observation
alone after ASCT. In contrast to the other studies, OS was
a primary endpoint in this trial. After a median follow-up pe-
riod of 4 years, thalidomide maintenance therapy yielded
an advantage for PFS, but not OS [13]. In another random-
ized trial that included both patients treated with ASCT and
those who were not, thalidomide maintenance therapy was
compared with observation only. Again, an advantage was
observed for PFS but not OS. Recently, another trial with a
larger number of patients showed again no benefits in
terms of OS, but an impact on PFS. Furthermore, for high-
risk patients defined by FISH, thalidomide maintenance
was deleterious and yielded no advantage in PFS and a
negative effect in OS [12]. These authors also performed a
meta-analysis including their results and results of overall
survival rates from IFM-9902, Spencer et al, TT2, and Lud-
wig et al. [3–5,17]. In this analysis, thalidomide had a sig-
nificant late benefit in terms of OS, but any conclusion
Figure 2. Overall survival (A) and PFS (B) for each treatment arm: Arm A: dexa-
methasone (n 5 52) and Arm B: dexamethasone 1 thalidomide (n 5 56). Kaplan-
Meier survival curve with curve comparison using the log rank test.
Figure 3. PFS according to the treatment arm and the disease status at random-
ization: (A) Complete response (CR) or very good partial response (VGPR) and
(B) No CR or VGPR. Kaplan-Meier survival curve with curve comparison using the
log rank test.
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must take account that these trials have important differen-
ces regarding ASCT and thalidomide strategy.
The rate of Grade III and IV adverse events in our trial
was higher in the thalidomide arm, similar to other studies
[3,4]. However, we observed a lower rate of thalidomide
discontinuation due to adverse events as compared with
these studies. While the reasons for these differences are
not known, a possible explanation may be the fact that we
strongly encouraged the investigators to reintroduce thali-
domide at a lower dose as soon as symptoms improved.
Peripheral neuropathy is a major adverse event that limits
prolonged maintenance with thalidomide. The introduction
of lenalidomide has opened a new perspective because it
has more potent immunomodulatory effects, and its use is
not associated with peripheral neuropathy [18]. Indeed,
lenalidomide maintenance after ASCT was explored in two
large phase 3 trials. Both trials showed a clear benefit for
lenalidomide versus placebo for PFS, with a very low inci-
dence of peripheral neuropathy [19,20]. In one of these tri-
als, there was a benefit for overall survival in the lenalido-
mide treatment arm [20]. An increased rate of second pri-
mary cancers was observed in the lenalidomide group in
both studies.
A major limitation of our study is that almost half of the
patients initially included in the study did not receive
the scheduled ASCTand therefore were not randomized. The
main cause of this loss was early death, related to infection in
60% of cases, and progression of myeloma in 32%. This is
likely a reflection of the high proportion of patients in Brazilian
hospitals with advanced disease at the time of diagnosis, as
reported by Hungria et al. in a large retrospective epidemio-
logic study of MM [21]. In conclusion, a maintenance strategy
using thalidomide and dexamethasone after a single ASCT
significantly improves PFS in patients with MM. Additional
studies are needed to assess whether this benefit is main-
tained with the incorporation of novel therapies.
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